Dr. Siddhartha Devarakonda
Claim this profileWashington University School of Medicine
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
15 reported clinical trials
31 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Non-Small Cell Lung Cancer
Stage III
Stage IV
PD-L1 positive
Affiliated Hospitals
Clinical Trials Siddhartha Devarakonda is currently running
APL-101
for Lung Cancer
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
Recruiting1 award Phase 211 criteria
Olomorasib
for Non-Small Cell Lung Cancer
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Recruiting1 award Phase 38 criteria
More about Siddhartha Devarakonda
Clinical Trial Related4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Siddhartha Devarakonda has experience with
- Atezolizumab
- Durvalumab
- Pembrolizumab
- Docetaxel
- APL-101
- SM08502
Breakdown of trials Siddhartha Devarakonda has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Siddhartha Devarakonda specialize in?
Siddhartha Devarakonda focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Siddhartha Devarakonda currently recruiting for clinical trials?
Yes, Siddhartha Devarakonda is currently recruiting for 6 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Siddhartha Devarakonda has studied deeply?
Yes, Siddhartha Devarakonda has studied treatments such as Atezolizumab, Durvalumab, Pembrolizumab.
What is the best way to schedule an appointment with Siddhartha Devarakonda?
Apply for one of the trials that Siddhartha Devarakonda is conducting.
What is the office address of Siddhartha Devarakonda?
The office of Siddhartha Devarakonda is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.